As IAVI’s President and CEO, Mark Feinberg draws on extensive experience in basic, translation, and clinical research and in advancing scientific and public health initiatives for the global control of HIV and other infectious diseases.
Most recently as Chief Public Health and Science Officer with Merck Vaccines, Feinberg helped advance access to and optimization of vaccines against rotavirus, human papillomavirus, and shingles. He also led the establishment of the MSD-Wellcome Trust Hilleman Laboratories in India that is dedicated to developing new vaccines to address unmet health needs in low-income countries and the coordination of a private-public partnership to expedite Ebola vaccine development. Previously, he spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both government and academia.
Feinberg holds an MD and a PhD from Stanford University, and a bachelor’s degree in Biology and Anthropology from the University of Pennsylvania. He pursued post-graduate medical training in Internal Medicine at the Brigham and Women’s Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute. He has previously served as a faculty member at the University of California, San Francisco, and the Emory University School of Medicine and as a Medical Officer in the Office of AIDS Research at the National Institutes of Health (NIH).
Feinberg is a Fellow of the American College of Physicians, a member of the Council on Foreign Relations and the Association of American Physicians, and the recipient of an Elizabeth Glaser Scientist Award from the Pediatric AIDS Foundation. He is Chair of the Scientific Advisory Committee of the Collaboration for Epidemic Preparedness Innovations and a member of the International Task Force on Strengthening Country Capacity for Vaccines Research and Development. He is also a member of the Council of the National Institute of Allergy and Infectious Diseases at the NIH.
Labeeb M. Abboud provides leadership on legal affairs, business development, intellectual property, risk management, and innovative finance initiatives. He advises the Board of Directors and CEO on governance and strategy, and is board chair of the IAVI-UVRI HIV Vaccine Program in Uganda. He is principally responsible for structuring IAVI’s collaborations and joint ventures with academic, industry, and public sector partners to ensure that any HIV vaccine developed will be globally accessible and affordable.
Abboud is Chairman of the Board of the Global Health Investment Fund, a Bill & Melinda Gates Foundation-sponsored social impact investment fund focused on accelerating late stage development of vaccines, drugs, diagnostics, and devices to address global health challenges in developing countries. He also serves on the Expert Advisory Group of the Medicines Patent Pool, which seeks to increase access to HIV, viral Hepatitis C, and tuberculosis treatments in low- and middle-income countries.
Prior to joining IAVI in 2004, he had 20 years of experience in the fields of international law and finance. He is a member of the Council on Foreign Relations, and has also served on the boards of several non-profit organizations. He is a graduate of Wesleyan University and Georgetown University Law Center.
Jill Gilmour’s comprehensive knowledge of HIV’s interaction with the human immune system comes from more than 20 years of HIV R&D experience. She is a founding member and Executive Director of IAVI’s Human Immunology Laboratory. She also leads IAVI’s Clinical Laboratory Program, overseeing research strategy, immune monitoring, data, quality, and scientific and laboratory capacity-building to support international HIV vaccine trials and epidemiology studies. She has helped 12 clinical laboratories in Africa and India come into being, shepherding them from founding through full accreditation.
Long focusing on the epidemic in Africa, she is a founder and Scientific Director of VISTA (Vaccine Immunology Science and Technology for Africa). In this capacity, she develops strategic partnerships to encourage collaboration, technology transfer, and training across Europe, the U.S., Africa, and India to design and assess AIDS vaccine candidates for Africa, with Africa.
Gilmour is Professor of Practice on the Imperial College London Faculty of Medicine and has an Honors Degree and PhD from the University of Edinburgh. She completed a post-doctoral fellowship with the U.K. Medical Research Council Direct Program of AIDS Research and helped the MRC/UVRI Uganda Research Unit on AIDS develop its cellular immunology laboratory.
Rajat Goyal has been working in cancer, HIV, and public health R&D for more than 20 years, and has overseen IAVI’s strategic direction in India since 2008.
In this role, he has helped establish key Government of India-led R&D initiatives and global collaborations, including the HIV Vaccine Translational Research (HVTR) Laboratory, as well as multilateral research partnerships facilitating North-South and South-South scientific cooperation. His contributions in ensuring national ownership and sustained investments in these programs have received widespread recognition. He also serves as an expert advisor for several organizations spanning government, industry, and academia.
Previously, he was Vice President of ICON, managing clinical operations for the Asia-Pacific region. Prior to that, he was Global Project Director at PATH’s Advancing Rotavirus Vaccine Development project, where he oversaw product development for vaccines and a range of other sustainable, ethical, and adaptive heath interventions. He also served as Vice President of Reliance Life Sciences’ Clinical Research Services in Mumbai.
Goyal studied medicine at King Edward Memorial Hospital in Mumbai, specializing in hemato-oncology. He completed a research fellowship at Rush Cancer Institute in Chicago, and visiting fellowships both at Beth Israel Deaconess Medical Center in Boston and at the Royal Marsden Hospital in London.
Swati Gupta provides expertise in integrating scientific initiatives and leveraging innovation for improved synergy and learning across IAVI’s R&D portfolio.
Previously, she was an Executive Director with Merck Vaccines, where she worked on the development of innovative partnership models to address cross-cutting issues related to vaccine science and technology. As part of this role, she worked with key external stakeholders to facilitate accelerated Ebola vaccine development efforts to enhance preparedness for the ongoing public health crisis and for potential future outbreaks.
From 2000 to 2014, Gupta was in the Department of Epidemiology at Merck Research Laboratories, where she led a number international prospective cohort studies in support of vaccine and infectious disease products in development, including research on diseases such as HIV, HPV, influenza, dengue, and C.difficile. From 1998 to 2000, Dr. Gupta worked as a scientist in HIV Surveillance at the Communicable Disease Surveillance Centre (British equivalent of the US CDC) in the U.K. She has also worked at the Bureau of Tuberculosis Control at the New York City Department of Health.
Gupta holds a doctorate in epidemiology from the Johns Hopkins Bloomberg School of Public Health and a master’s of public health infectious disease epidemiology from Yale University School of Medicine.
As the Vice President for Vaccine Development, Thomas Hassell leads IAVI’s efforts to rapidly advance the most promising HIV vaccine candidates from the lab bench to clinical trials and, ultimately, mature products.
He joined IAVI in 2008 after more than 20 years of industry experience with several leading vaccine developers. In his previous work, he led efforts to take early stage vaccine candidates for a number of humanity’s worst afflictions from ideas all the way through to licensure. Most recently, he led a team of 250 researchers as Global Vice President of Process Development at Sanofi Pasteur, the world’s largest vaccine producer. His teams successfully spearheaded national licensure of Pentacel, a childhood combination vaccine against diphtheria, tetanus, whooping cough, Haemophilus Influenzae Type B, and polio, as well as Menactra, the first conjugate vaccine to provide protection against four strains of bacterial meningitis. During his time at Sanofi Pasteur, Hassell also oversaw the launch of state-of-the-art vaccine development facilities in Canada, France, and the U.S.
Trained as a microbiologist, Hassell received his PhD from Manchester Metropolitan University in the U.K. in 1987 and completed a postdoctoral program at the Massachusetts Institute of Technology as a Rockefeller Foundation Fellow in 1989.
Anatoli Kamali leads IAVI’s Africa programs which include a wide partners’ network of clinical research centers and laboratories across five countries, as well as IAVI’s regional research portfolio. He oversees IAVI’s community engagement, research preparedness, policy, and advocacy activities in the region. Kamali is also an Honorary Professor, Department of Infectious Disease Epidemiology at the London School of Hygiene and Tropical Medicine.
Before joining IAVI, he was the deputy director and head of the HIV Epidemiology and Prevention Research Program at the Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) Unit on AIDS, and in that capacity led the MRC’s collaboration with IAVI. He led various clinical studies of HIV vaccine candidates and vaginal microbicides, including the institute’s participation in trials of a monthly vaginal dapivirine ring in collaboration with International Partnership for Microbicides (IPM). He has helped enhance community engagement in research and conduct numerous epidemiological studies. He also chaired the Protocol C Scientific Steering Committee.
He has served as a member of the International Data and Safety Monitoring Board of the Division of AIDS at the U.S. National Institute of Allergy and Infectious Diseases for various clinical trials in Africa, and as temporary advisor on sexual and reproductive health to the World Health Organization.
Kamali qualified in Medicine and Surgery at Makerere University in Kampala, Uganda, has an MSc in Community Health at London School of Hygiene and Tropical Medicine and a PhD from City University, London. He has published over 100 scientific peer reviewed articles and book chapters.
Margaret “Maggie” Keane ensures the creation of IAVI target product profiles that are informed by the needs of vulnerable populations which continue to bear the brunt of the HIV/AIDS epidemic.
In this role, Keane employs systematic and strategic engagement with key external stakeholders, including industry partners, to optimize design and development approaches aimed at expediting the development of AIDS vaccines and other new biomedical HIV prevention tools. She also helps advance IAVI's product development programs using new investment models.
Previously at Merck for 30 years, Keane was responsible for designing and implementing novel external-collaboration models and financing mechanisms to facilitate product development and expand access to Merck vaccines and medicines. She helped to identify the most promising scientific opportunities, secured federal funding for Ebola vaccine development and philanthropic grant funding, and managed a board of external experts to inform strategies on cross-cutting issues such as the global disease burden, public health preparedness, commercial excellence, and R&D portfolio prioritization. She also she served as an Alliance Manager to the MSD Wellcome Trust Hilleman Laboratories to develop new and optimized vaccines to meet the needs of developing countries.
Keane was a Global Health Fellow (Pathfinder International and World Health Partner) in India and holds an MBA in marketing from Villanova University.
Margaret Lidstone is responsible for the design and implementation of IAVI’s fundraising strategy and helps drive outreach and relationships with donors, philanthropists and key policymakers globally.
Previously, she was Director of Multilateral Diplomacy for the Office of the U.S. Global AIDS Coordinator with the President’s Emergency Plan for AIDS Relief (PEPFAR). There she coordinated U.S. government engagement with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and key teams at the World Health Organization (WHO), as well as liaising with PEPFAR’s main bilateral partners. She also represented the U.S. Secretary of Health and Human Services in his capacity as the Chair of the Board of Directors for the Global Fund.
Prior to PEPFAR, she helped lead the international health practice at Booz Allen Hamilton and was an associate at Covington and Burling corporate law firm. She also headed the Division of Media Regulation, Laws and Standards for the United Nations transitional authority in Kosovo, where she helped develop legal and governance structures for the province’s print and broadcast media.
She holds a doctorate in law from the University of Michigan and a bachelor’s degree in religious studies from the University of Wisconsin-Madison.
Frances Priddy oversees clinical evaluation of HIV vaccine and prevention candidates at IAVI, including replicating and non-replicating viral vectors, DNA and protein subunit vaccines, monoclonal antibodies, and gene transfer. She also supervises the epidemiology program, including IAVI’s landmark Protocol G study to identify broadly neutralizing HIV antibodies, as well as the clinical aspects of its training and capacity-building programs in Africa.
Priddy has more than 15 years’ experience in vaccine clinical development, and 25 years’ experience in global health, prevention research and international collaborations. She currently leads a global team conducting first-in-human and multi-center trials in Africa, the U.S., and Europe and is responsible for clinical strategy, trial design, clinical operations, data management and analysis, clinical quality assurance, and protection of trial volunteers.
Previously, she was Medical Director of the Emory Vaccine Center’s clinical trials site and Principal Investigator for eight HIV vaccine and microbicide trials. She served as an Assistant Professor in the Emory University School of Medicine and conducted research and HIV-related field work in Zambia, Ethiopia, Kenya, Malawi and Zaire. Priddy is Board-certified in internal medicine and holds a Master of Public Health degree from the University of California, Berkeley. She received her MD from the University of California, San Francisco.
Louis Schwartz has managed IAVI’s financial operations since 2012 as the leader of the organization’s Finance & Administration team. In this role, he supervises IAVI’s global financial planning and forecasting, grants and contracts, audit and compliance, knowledge management, and information technology.
Schwartz has more than 30 years of experience in international finance and management in both the public and private sectors. Before joining IAVI, he served as Vice President for Finance and Administration at the international development organization American Jewish World Service, where he oversaw the organization’s annual budget of US$50 million and led the finance, IT, human resources, and facilities teams. Prior to that, he was Chief Financial Officer of the nonprofit Neighborhood Housing Services of NYC and at one of the largest Russian investment banks, Troika Dialog Russia. He also held various leadership positions in finance in commercial banking in Moscow and New York City.
He is a member of the CFO Roundtable and the Bridgestar New York Non-Profit CFO Network. He sits on the boards of several nonprofits, and is a member of the Dobbs Ferry School District’s Board of Education. Schwartz holds a bachelor’s degree in business administration from Georgetown University and attended the University of Chicago’s Booth School of Business.